Related Experiment Video
Updated: Feb 13, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Abstract:
In a recent study, organoids derived from the metastatic tumors of patients with gastrointestinal cancers had a similar response to treatment as the original tumors. Eventually, organoids could become a useful tool for identifying the most effective therapy for each patient.
Insights
Organoids from metastatic gastrointestinal cancer tumors mirrored original tumor treatment responses. These patient-derived organoids show promise for personalized cancer therapy selection.
Area of Science:
- Oncology
- Translational Medicine
- Cancer Research
Background:
- Metastatic gastrointestinal cancers present significant treatment challenges.
- Patient-derived organoids (PDOs) are emerging as preclinical models for cancer research.
Discussion:
- This study investigated the therapeutic response fidelity between primary tumors and their corresponding organoids in gastrointestinal cancer patients.
- Organoids accurately reflected the in vivo response of the original tumors to various treatments, including chemotherapies and targeted agents.
Key Insights:
- Organoid models derived from metastatic gastrointestinal tumors exhibit similar treatment responses to the parent tumors.
- This suggests organoids can reliably predict patient response to specific therapies.
Outlook:
- Organoids offer a potential avenue for personalized medicine in gastrointestinal oncology.
- Further validation could establish organoids as a standard tool for pre-treatment therapy selection, improving patient outcomes.
More Related Videos
Related Concept Videos
Gene Therapy
Group Therapy
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Drug Therapy
Antianxiety Medications
Cognitive Therapy
Electroconvulsive Therapy

